Citigroup has maintained a Neutral rating on Regeneron Pharmaceuticals due to increasing competition in the ophthalmology sector. Kodiak Sciences reported positive Phase 3 trial results for its eye drugs, challenging Regeneron's key product, Eylea, especially for wet age-related macular degeneration. Despite this, Regeneron continues to innovate, recently receiving FDA approval for its Eylea HD injection for macular edema after retinal vein occlusion. The competition has impacted Regeneron's stock price, which fell by nearly 4% following Kodiak's trial success.
Regeneron Pharmaceuticals is navigating a competitive landscape in ophthalmology as noted by Citigroup's Neutral rating. On Pluang, REGN shares are trading at USD 751.10, down 4.69% as of Sep 29, 2026 02:52 WIB, reflecting recent market reactions. The stock's market cap stands at $81.13 billion, with a 52-week range between $557.73 and $852.03, and a dividend yield of 0.48%.
